How TET2 and IDH2 gene changes drive angioimmunoblastic T‑cell lymphoma
Cooperative role of TET2 and IDH2 mutations in angioimmunoblastic T-cell lymphomagenesis
Researchers are looking at whether specific changes in the TET2 and IDH2 genes together cause angioimmunoblastic T‑cell lymphoma (AITL) and how that might be stopped.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-11143640 on NIH RePORTER |
What this research studies
This project uses mouse models and patient-derived tumor grafts to study how loss of TET2 and a specific IDH2 mutation (R172) change CD4+ T cells and lead to AITL. Researchers will examine DNA methylation and gene activity to see how these mutations push T cells toward a follicular helper T‑cell (TFH) identity and clonal expansion. You might be asked to donate tumor tissue or blood samples if you have AITL with these mutations so researchers can grow patient-derived models. The team aims to connect the gene changes to T‑cell behavior and identify pathways that could be targeted by new treatments.
Who could benefit from this research
Good fit: People diagnosed with angioimmunoblastic T‑cell lymphoma, especially those whose tumors carry TET2 and/or IDH2R172 mutations, would be ideal candidates to contribute samples or participate in related studies.
Not a fit: People with other types of lymphoma or without TET2/IDH2 mutations are unlikely to see direct benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to better diagnostic markers and targeted therapies for people with AITL.
How similar studies have performed: Prior genomic studies and animal models have linked TET2 and IDH2 mutations to AITL and suggested cooperative effects, but translating that knowledge into therapies is still an active and emerging area.
Where this research is happening
Omaha, United States
- University of Nebraska Medical Center — Omaha, United States (Active)
Researchers
- Principal investigator: Iqbal, Javeed — University of Nebraska Medical Center
- Study coordinator: Iqbal, Javeed
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.